COMMUNIQUÉS West-GlobeNewswire
-
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
30/06/2026 -
NurExone Announces Closing of Non-Brokered Private Placement
30/06/2026 -
iKrusher Invests in Canadian Operations to Improve Supply Chain Reliability and Speed to Market for Vape Brands
30/06/2026 -
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
30/06/2026 -
MediciNova CEO Provides Shareholder Update
30/06/2026 -
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
30/06/2026 -
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
30/06/2026 -
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
30/06/2026 -
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
30/06/2026 -
FEATOL Rolls Out Reinforced Lower Back Brace to Help Adults During Work, Driving, and in Chronic Pain
30/06/2026 -
R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease
30/06/2026 -
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
30/06/2026 -
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
30/06/2026 -
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
30/06/2026 -
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
30/06/2026 -
Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial
30/06/2026 -
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
30/06/2026 -
TerrAscend Signs Agreement to Acquire Fifth Dispensary in New Jersey
30/06/2026 -
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
30/06/2026
Pages